SCHEMBL13650538

SCHEMBL13650538

Nc1nc(NCCC2CCCCN2)c2c(n1)C(c1ccccc1)CCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 2/20 0.51
▸ HRH3 Q9Y5N1 2/20 0.51
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ PHLPP2 Q6ZVD8 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ F2 P00734 3/20 0.36
▸ F10 P00742 3/20 0.36
▸ PLAT P00750 2/20 0.36
▸ PRSS1 P07477 2/20 0.36
▸ PRSS2 P07478 2/20 0.36
▸ PRSS3 P35030 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ METAP2 P50579 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13650647 0.93 HRH3 (0.51) HRH4HRH3METAP2HRH2APP
SCHEMBL13650542 0.91 HRH4 (0.48) HRH4HRH3CYP1A2CYP2D6CYP2C19
SCHEMBL13650535 0.90 HRH4 (0.53) HRH4HRH3IRAK4POLBHRH2
SCHEMBL13650618 0.87 HRH4 (0.52) HRH4HRH3IRAK4HRH2APP
SCHEMBL13650537 0.87 HRH4 (0.52) HRH4HRH3IRAK4HRH2APP
SCHEMBL13650531 0.83 HRH3 (0.53) HRH4HRH3HRH2APPPRMT5
SCHEMBL13650467 0.82 HRH4 (0.51) HRH4HRH3IRAK4HRH2APP
SCHEMBL13650554 0.81 HRH3 (0.46) HRH4HRH3HRH2APP
SCHEMBL13650528 0.80 HRH3 (0.52) HRH4HRH3HRH2HRH1
SCHEMBL13650525 0.80 HRH3 (0.52) HRH4HRH3HRH2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 — — WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH4 3370/4885HRH3 3555/4885CYP1A2 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback